JPS59130215A - 錐体外運動障害の軽減法 - Google Patents
錐体外運動障害の軽減法Info
- Publication number
- JPS59130215A JPS59130215A JP58242302A JP24230283A JPS59130215A JP S59130215 A JPS59130215 A JP S59130215A JP 58242302 A JP58242302 A JP 58242302A JP 24230283 A JP24230283 A JP 24230283A JP S59130215 A JPS59130215 A JP S59130215A
- Authority
- JP
- Japan
- Prior art keywords
- buspirone
- extrapyramidal
- movement disorder
- extrapyramidal movement
- catalepsy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 claims description 25
- 208000016285 Movement disease Diseases 0.000 claims description 17
- 229960002495 buspirone Drugs 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 10
- 208000027776 Extrapyramidal disease Diseases 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 8
- 229960001768 buspirone hydrochloride Drugs 0.000 claims description 8
- 210000000653 nervous system Anatomy 0.000 claims description 7
- 208000018737 Parkinson disease Diseases 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 3
- 231100000252 nontoxic Toxicity 0.000 claims 2
- 230000003000 nontoxic effect Effects 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000009132 Catalepsy Diseases 0.000 description 20
- 206010047853 Waxy flexibility Diseases 0.000 description 20
- 241001465754 Metazoa Species 0.000 description 16
- 229940079593 drug Drugs 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 9
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 8
- 238000011282 treatment Methods 0.000 description 7
- 241000700159 Rattus Species 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 239000002249 anxiolytic agent Substances 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229960003638 dopamine Drugs 0.000 description 4
- 208000022084 motor paralysis Diseases 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 3
- 230000000949 anxiolytic effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 229950000688 phenothiazine Drugs 0.000 description 3
- -1 pyrimidine compound Chemical class 0.000 description 3
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001713 cholinergic effect Effects 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- ZEWQUBUPAILYHI-UHFFFAOYSA-N trifluoperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 ZEWQUBUPAILYHI-UHFFFAOYSA-N 0.000 description 2
- 229960002324 trifluoperazine Drugs 0.000 description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000031872 Body Remains Diseases 0.000 description 1
- NOQGZXFMHARMLW-UHFFFAOYSA-N Daminozide Chemical compound CN(C)NC(=O)CCC(O)=O NOQGZXFMHARMLW-UHFFFAOYSA-N 0.000 description 1
- 241001397104 Dima Species 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 208000015592 Involuntary movements Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 206010047697 Volvulus Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 1
- 229910001573 adamantine Inorganic materials 0.000 description 1
- 230000003270 anti-cataleptic effect Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 208000018300 basal ganglia disease Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
- 229960002802 bromocriptine Drugs 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000002903 catalepsic effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- WTVNFKVGGUWHQC-UHFFFAOYSA-N decane-2,4-dione Chemical compound CCCCCCC(=O)CC(C)=O WTVNFKVGGUWHQC-UHFFFAOYSA-N 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000000534 dopa decarboxylase inhibitor Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 210000004744 fore-foot Anatomy 0.000 description 1
- 230000003483 hypokinetic effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 201000007647 intestinal volvulus Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 230000017311 musculoskeletal movement, spinal reflex action Effects 0.000 description 1
- 229940000041 nervous system drug Drugs 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 238000012346 open field test Methods 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Chemical class 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001003 psychopharmacologic effect Effects 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 230000000506 psychotropic effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000028527 righting reflex Effects 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 230000021542 voluntary musculoskeletal movement Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/452,686 US4438119A (en) | 1982-12-23 | 1982-12-23 | Method for alleviation of extrapyramidal motor disorders |
| US452686 | 1982-12-23 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS59130215A true JPS59130215A (ja) | 1984-07-26 |
| JPH0422889B2 JPH0422889B2 (cg-RX-API-DMAC7.html) | 1992-04-20 |
Family
ID=23797489
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP58242302A Granted JPS59130215A (ja) | 1982-12-23 | 1983-12-23 | 錐体外運動障害の軽減法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US4438119A (cg-RX-API-DMAC7.html) |
| JP (1) | JPS59130215A (cg-RX-API-DMAC7.html) |
| AU (1) | AU556112B2 (cg-RX-API-DMAC7.html) |
| BE (1) | BE898540A (cg-RX-API-DMAC7.html) |
| DE (1) | DE3346237A1 (cg-RX-API-DMAC7.html) |
| PH (1) | PH18968A (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA839451B (cg-RX-API-DMAC7.html) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4634703A (en) * | 1985-10-25 | 1987-01-06 | Bristol-Myers Company | Method for alleviation of panic disorders |
| US4640921A (en) * | 1986-02-04 | 1987-02-03 | Bristol-Myers | Treatment of sexual dysfunction with buspirone |
| US4687772A (en) * | 1986-10-07 | 1987-08-18 | Bristol-Myers Company | Method for improvement of short term memory |
| US4777173A (en) * | 1987-03-25 | 1988-10-11 | Bristol-Myers Company | Method for treatment of alcohol abuse |
| DE3736974A1 (de) * | 1987-10-31 | 1989-05-11 | Troponwerke Gmbh & Co Kg | Verwendung von 2-pyrimidinyl-1-piperazin-derivaten |
| US5468749A (en) * | 1988-08-30 | 1995-11-21 | Gawin; Frank H. | Method for treatment of substance addiction |
| US6432956B1 (en) | 1990-02-12 | 2002-08-13 | William C. Dement | Method for treatment of sleep apneas |
| US5633009A (en) * | 1990-11-28 | 1997-05-27 | Sano Corporation | Transdermal administration of azapirones |
| US5824680A (en) * | 1991-08-31 | 1998-10-20 | Bayer Aktiengesellschaft | Ipsapirone for the treatment of alzheimer's disease by improving memory |
| US5631017A (en) * | 1993-03-26 | 1997-05-20 | Beth Israel Deaconess Medical Center, Inc. | Topical application of buspirone for treatment of pathological conditions associated with immune responses |
| US5484788A (en) * | 1993-03-26 | 1996-01-16 | Beth Israel Hospital Association | Buspirone as a systemic immunosuppressant |
| US5637314A (en) * | 1995-06-07 | 1997-06-10 | Beth Israel Deaconess Medical Center, Inc. | Topical and systemic application of buspirone or derivatives thereof for treating atopic dermatitis |
| UA73981C2 (en) * | 2000-03-10 | 2005-10-17 | Merck Patent Gmbh | (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane for treatment of extrapyramidal movement disorders (variants), pharmaceutical composition and kit |
| US7053092B2 (en) | 2001-01-29 | 2006-05-30 | Otsuka Pharmaceutical Co., Ltd. | 5-HT1a receptor subtype agonist |
| PL208258B1 (pl) * | 2001-07-26 | 2011-04-29 | Merck Patent Gmbh | Nowe zastosowanie 2-[5-(4-fluorofenylo) -3- pirydylometyloaminometylo] -chromanu oraz jego fizjologicznie tolerowanych soli |
| AR033485A1 (es) | 2001-09-25 | 2003-12-26 | Otsuka Pharma Co Ltd | Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma |
| AR055424A1 (es) * | 2005-09-12 | 2007-08-22 | Wyeth Corp | Formulacion de liberacion sostenida y usos de la misma |
| GT200600414A (es) * | 2005-09-12 | 2007-09-20 | Sal de glucuranato de compuesto de piperazine | |
| GT200600416A (es) * | 2005-09-12 | 2007-09-20 | Sales salicilato y gentisato de un compuesto de piperazina | |
| AU2011316225B2 (en) * | 2010-10-15 | 2016-05-19 | Contera Pharma Aps | Combinations of serotonin receptor agonists for treatment of movement disorders |
| BR112014025907B1 (pt) | 2012-04-18 | 2023-02-14 | Contera Pharma Aps | Formulação farmacêutica disponível para administração por via oral adequada para manejo aprimorado de transtornos do movimento |
| HUE039750T2 (hu) * | 2014-06-26 | 2019-02-28 | Contera Pharma Aps | Hidroxi-buspiron mozgászavarok kezelésére |
| AU2017297718B2 (en) | 2016-07-11 | 2023-06-08 | Contera Pharma A/S | Pulsatile drug delivery system for treating morning akinesia |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS54163587A (en) * | 1978-05-22 | 1979-12-26 | Bristol Myers Co | Buspirone antiineurosis |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE759371A (fr) | 1969-11-24 | 1971-05-24 | Bristol Myers Co | Azaspirodecanediones heterocycliques et procedes pour leur preparation |
| US3976776A (en) | 1972-12-06 | 1976-08-24 | Mead Johnson & Company | Tranquilizer process employing N-(heteroarcyclic)piperazinylalkylazaspiroalkanediones |
-
1982
- 1982-12-23 US US06/452,686 patent/US4438119A/en not_active Expired - Lifetime
-
1983
- 1983-12-20 ZA ZA839451A patent/ZA839451B/xx unknown
- 1983-12-21 DE DE19833346237 patent/DE3346237A1/de not_active Withdrawn
- 1983-12-22 BE BE0/212106A patent/BE898540A/fr not_active IP Right Cessation
- 1983-12-22 AU AU22793/83A patent/AU556112B2/en not_active Expired
- 1983-12-23 JP JP58242302A patent/JPS59130215A/ja active Granted
- 1983-12-23 PH PH30027A patent/PH18968A/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS54163587A (en) * | 1978-05-22 | 1979-12-26 | Bristol Myers Co | Buspirone antiineurosis |
Also Published As
| Publication number | Publication date |
|---|---|
| AU556112B2 (en) | 1986-10-23 |
| PH18968A (en) | 1985-11-26 |
| AU2279383A (en) | 1984-06-28 |
| ZA839451B (en) | 1984-09-26 |
| JPH0422889B2 (cg-RX-API-DMAC7.html) | 1992-04-20 |
| BE898540A (fr) | 1984-06-22 |
| DE3346237A1 (de) | 1984-07-05 |
| US4438119A (en) | 1984-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS59130215A (ja) | 錐体外運動障害の軽減法 | |
| Redmond et al. | Fetal neuronal grafts in monkeys given methylphenyltetrahydropyridine | |
| AU2017210644B2 (en) | Autoimmune disorder treatment using RXR agonists | |
| US6555576B1 (en) | Method for treating exercise induced asthma | |
| US5116852A (en) | Treatment of sleep disorders | |
| JPH05201859A (ja) | 神経障害治療剤 | |
| Bonta et al. | 1-Hydroxy-3-amino-pyrrolidone-2 (HA-966): a new GABA-like compound, with potential use in extrapyramidal diseases | |
| JP2002532393A (ja) | エキソ−ｒ−メカミラミン製剤および治療におけるその使用 | |
| DE69808619T2 (de) | Prostaglandin-pharmazeutische-zusammensetzungen | |
| US20250352540A1 (en) | Uses of a pure 5-ht6 receptor antagonist | |
| CN101484004A (zh) | 新型大麻素及使用方法 | |
| Tainter | Effects of certain analeptic drugs on spontaneous running activity of the white rat. | |
| JPH09323927A (ja) | 慢性閉塞性動脈硬化症の治療のためのカルニチン誘導体含有薬剤 | |
| Hill et al. | Reduction of pain-conditioned anxiety by analgesic doses of morphine in rats | |
| JP2002518442A (ja) | 偏頭痛及び情動病の治療及び予防用バルプロ酸類似物の用法 | |
| US6143782A (en) | Anti-inflammatory and anti-asthma treatment with reduced side effects | |
| UA42686C2 (uk) | Похідні 3-хінуклідилових ефірів, проміжні сполуки та спосіб одержання 3-хінуклідилових ефірів, фармацевтична композиція, що має антимускаринову дію, та спосіб лікування хронічних обструктивних захворювань дихальних шляхів або астми | |
| Mendelson et al. | Lifetime monoamine oxidase inhibition and sleep | |
| CA2366036A1 (en) | Method for treating copd | |
| CN109310669B (zh) | 氨基甲酸酯化合物用于预防或治疗三叉神经痛的用途 | |
| JP2000507205A (ja) | 眼の虚血障害の治療薬の製造のためのポリアミン部位拮抗物質の使用 | |
| JP3043807B2 (ja) | 加齢関連記憶障害およびその他の認識障害の治療のための化合物 | |
| WO1997002822A1 (en) | Drug for ameliorating brain diseases | |
| CN103054842A (zh) | N-(2-芳基-丙酰基)-磺酰胺在制备治疗脊髓损伤用的药物中的用途 | |
| EP0442424A1 (en) | Treatment of sleep apneas with azapirone derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EXPY | Cancellation because of completion of term |